Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Path to IPO: Preparing for Success

Summary

Speakers

Sarah Ashfaq

Related Content

SEC Issues Section 21(a) Report on Investor Coalitions, “Group” Formation, and Schedule 13G Eligibility

Sanofi and Regeneron Expand Immunology Collaboration in Deal Worth Up to $8 Billion

Celltrion Launches Omalizumab Biosimilar in the United States

Sandoz and mABxience Announce Collaboration for Proposed Emicizumab Biosimilar

Stopping Disputes Before They Derail Innovation: The Emerging Role of Life Sciences Dispute Review Boards

Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach

Nektar v. Lilly: Lilly Defeats CRE Claim, but Jury Finds It Owes $90M for Breaching the Implied Covenant of Good Faith and Fair Dealing

Preliminary Injunctive Relief in Trade Secret Cases: When to Move and What to Prove

Goodwin Advises OMass Therapeutics on $310 Million Series C

Goodwin’s UK Platform Highly Ranked in Chambers UK 2027

Goodwin Advises insitro in Strategic Collaboration With AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Goodwin Advises TRex Bio on Intellectual Property Aspects for $117 Million Initial Public Offering

Barry Z. Bazian Named to American Bankruptcy Institute’s 40 Under 40

Goodwin Advises BioGeneration Ventures, Angelini Ventures, and Kurma Partners on $58 Million Series A Financing of RougeTx

Goodwin Advises Repligen Corporation on the Acquisition of BioLife Solutions

Goodwin Advises Alentis on Global Collaboration Agreement With CSL for $355 Million Upfront and Up to $1.2 Billion in Milestone Payments and Worldwide Profit Share

Life Sciences

Life Sciences IPOs & Capital Markets